Cerecor to Present at 16th Annual BIO CEO & Investor Conference

Baltimore, MD, February 5, 2014 – Cerecor Inc., a clinical stage biopharmaceutical company developing prescription pharmaceuticals that work in the human nervous system and address the needs of underserved patient segments of major diseases, today announced that Blake Paterson, MD, CEO and Co-founder, will present at the 16th Annual BIO CEO & Investor Conference taking place February 10-11, 2014, in New York, NY. Dr. Paterson will provide an overview of the Company’s lead candidate, CERC-301, a once daily, oral, adjunctive, selective NMDA receptor subunit 2B (NR2B) antagonist with the potential to be the first in a new class of rapidly acting antidepressants, which is currently in a Phase 2 study. In addition, Dr. Paterson will discuss Cerecor’s COMT inhibitor platform for the treatment of cognitive impairment in conditions where loss of executive function is a key symptom. The presentation will take place Monday, February 10 at 10:30am ET.

This entry was posted in Recent Development News: Q1 - 2014. Bookmark the permalink.